Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 12/20 | 0.42 |
| ▸ | TOP2B | Q02880 | 9/20 | 0.42 |
| ▸ | TOP1 | P11387 | 5/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | MATK | P42679 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abt-719 SCHEMBL8569278 | 1.00 | ALDH1A1 (0.46) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| Abt-719 SCHEMBL1290350 | 1.00 | ALDH1A1 (0.46) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| Abt-719 SCHEMBL7496844 | 0.99 | ALDH1A1 (0.45) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| Abt-719 SCHEMBL7507152 | 0.99 | ALDH1A1 (0.45) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| Abt-719 SCHEMBL7496841 | 0.99 | ALDH1A1 (0.45) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL8561704 | 0.94 | SCN5A (0.42) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL12590147 | 0.94 | SCN5A (0.42) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL8564917 | 0.94 | SCN5A (0.42) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL8601235 | 0.94 | SCN5A (0.42) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| Hydrochloric Acid SCHEMBL7500979 | 0.93 | SCN5A (0.42) | ALDH1A1POLBCHRM2CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | claimed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | claimed |
| US-20180296555-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2018-10-18 | — | — | US | disclosed |
| EP-2621491-B1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EMERGENT PRODUCT DEV GAITHERSBURG INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20170209437-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2017-07-27 | — | — | US | disclosed |
| EP-3034078-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | Emergent Product Development Gaithersburg Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| US-20150141435-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2015-05-21 | — | — | US | disclosed |
| US-8962842-B2 | 2-pyridone antimicrobial compositions | EVOLVA SA (CH) | 2015-02-24 | — | — | US | disclosed |
| US-20130245035-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2013-09-19 | — | — | US | disclosed |
| EP-2621491-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | Evolva SA (CH) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012047487-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2012-04-12 | — | — | WO | disclosed |
| WO-2006012470-A1 | RIFAMYCIN DERIVATIVES FOR TREATING MICROBIAL INFECTIONS | CUMBRE PHARMACEUTICALS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060019985-A1 | Rifamycin derivatives | CUMBRE INC. (US) | 2006-01-26 | — | — | US | disclosed |
| EP-0723545-B1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LAB (US) | 2002-05-08 | — | — | EP | disclosed |
| CN-1053188-C | Quinolizinone type compounds | ABBOTT LAB (US) | 2000-06-07 | — | — | CN | disclosed |
| EP-0871628-A1 | QUINOLIZINONE TYPE COMPOUNDS | Abbott Laboratories (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5580872-A | ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019985-A1 | Rifamycin derivatives | RIF1, NQO1, MRM1 | ALDH1A1 385/4885POLB 710/4885CHRM2 2924/4885 |
| US-20180296555-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | TOP2A, TOP1, TOP2B | ALDH1A1 3063/4885POLB 19/4885CHRM2 2974/4885 |
| US-20150141435-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | TOP2A, TOP1, TOP2B | ALDH1A1 3063/4885POLB 19/4885CHRM2 2974/4885 |
| US-20130245035-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | TOP2A, TOP1, TOP2B | ALDH1A1 3718/4885POLB 16/4885CHRM2 3212/4885 |
| US-20170209437-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | TOP2A, TOP1, TOP2B | ALDH1A1 3063/4885POLB 19/4885CHRM2 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.